SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc.
NNVC 1.660-2.4%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Straynut who wrote (12780)5/26/2020 8:57:41 AM
From: old 'n cranky  Read Replies (1) of 12871
 
HCoV-NL63 can be used in a BSL2 lab whereas SARS-CoV-2 currently requires BSL3/BSL4 labs. Therefore, the Company believes hCoV-NL63 serves as a useful model for drug development against SARS-CoV-2.


Can you explain that?
They seem to be saying that the reason that the HCoV-NL63 model is useful doesn't have anything to do with a particular characteristic of that virus but rather that it can be used for testing in the NanoViricides BSL2 lab.

That makes it useful for NanoViricides, but does it make it especially useful as a model?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News